This observational cross-sectional case-control study aims to evaluate the effects of menopausal status on escitalopram metabolism in women. The study will include premenopausal and menopausal women aged 40-60 years who are currently receiving escitalopram treatment and have applied to the Psychiatry Clinic of Eskişehir Osmangazi University. The study aims to identify pharmacokinetic differences associated with hormonal status and to investigate their potential clinical implications. Findings from this research are expected to contribute to the development of evidence-based, individualized treatment strategies for women in menopausal transition.
Aged 40 years or older and 60 years or younger
Diagnosed with major depressive disorder and/or generalized anxiety disorder by an independent psychiatrist (not a member of the research team)
Prescribed escitalopram treatment by an independent psychiatrist (not a member of the research team)
Receiving escitalopram treatment for at least one month and on a stable dose for at least one week
Diagnosis of intellectual disability, dementia, psychotic disorders, schizoaffective disorder, or bipolar disorder
Alcohol or substance use disorder
Diagnosis of hepatic failure, renal failure, or cardiac failure
Severe malnutrition
Eskisehir Osmangazi University
Lead sponsor
The Scientific and Technological Research Council of Turkey
Collaborator